Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC

This is a prospective observational clinical study designed to predict the therapeutic efficacy of first-line treatment with tislelizumab combined with standard chemotherapy in patients with ES-SCLC using TCR repertoire technology. The study plans to enroll 40 treatment-naive patients with ES-SCLC.

NCT Number	NCT07244016
Lead Sponsor	Henan Cancer Hospital
Conditions	Extensive-stage Small-cell Lung Cancer
Enrollment	40 participants
Start Date	2025-02-20
Primary Completion	2026-12-30 (estimated)
Study Completion	2027-07-01 (estimated)
Updated on ClinicalTrials.gov	2025-11-24